NCT07753317Not yet recruiting
Clinical and Radiographic Evaluation of Subgingival 1% Metformin Gel Versus 0.05% Zoledronate Gel as an Adjunct to MINST of Intrabony Defects in Controlled Type 2 DM
Clinical and Radiographic Evaluation of Subgingival 1% Metformin Gel Versus 0.05% Zoledronate Gel as an Adjunct to Minimally Invasive Nonsurgical Treatment of Intrabony Defects in Controlled Type 2 Diabetic Patients With Periodontitis. A Placebo Randomized Controlled Trial.
Source: ClinicalTrials.gov · Last updated 11 Aug 2026
Brief summary (registry, in English)
The present randomized placebo-controlled trial aims to evaluate and compare the clinical and radiographic efficacy of subgingivally delivered 0.05% zoledronate gel and 1% metformin gel as adjuncts to minimally invasive nonsurgical treatment of intrabony defects in patients with controlled type 2 diabetes mellitus and periodontitis.
- Status (registry)
- Not yet recruiting
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- First submitted
- 4 Aug 2026
- Start date
- 7 Aug 2026
- Primary completion date
- 7 Feb 2027
- Lead sponsor
- Cairo University
- Diseases
- Type 1 diabetes, Type 2 diabetes
- NCT number
- NCT07753317
What you commit to
- Study type: Interventional
- Planned participants: 30
- From 7 Aug 2026 to the primary completion date, 7 Feb 2027
- No sites listed in no country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients on systemic bisphosphonate therapy or other medications known to affect bone metabolism.
Other illness
- History of radiation therapy to the head and neck
Lab values
- Uncontrolled diabetes (HbA1c \>8%) or other systemic diseases that could affect periodontal status.
Other
- Smokers.
- Pregnant or lactating women.
Who the study is looking for
- Diagnosed with type 2 diabetes mellitus, with HbA1c levels \<7.0% (controlled).
- Diagnosis of chronic periodontitis (Stage III/IV, Grade B/C) with at least one intrabony defect of ≥3 mm depth, PPD ≥5 mm, and CAL ≥4 mm measured with a calibrated UNC-15 probe.
- Angular bone loss of ≥3 mm measured on digital intraoral periapical radiographs and having three walled intrabony defects without involving furcation confirmed on cone beam computed tomography (CBCT).
Age in the registry: 30 years to 60 years · Sex: All · Accepts healthy volunteers
This page is information, not medical advice. Discuss any trial with your doctor.